Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Get Free Report)'s share price gapped up prior to trading on Friday . The stock had previously closed at $7.87, but opened at $8.21. Olema Pharmaceuticals shares last traded at $8.77, with a volume of 170,506 shares trading hands.
Analyst Upgrades and Downgrades
A number of research analysts recently issued reports on OLMA shares. JPMorgan Chase & Co. lowered their target price on Olema Pharmaceuticals from $33.00 to $31.00 and set an "overweight" rating on the stock in a report on Thursday, August 8th. Oppenheimer reaffirmed an "outperform" rating and issued a $30.00 price objective on shares of Olema Pharmaceuticals in a research note on Wednesday, August 7th. Finally, HC Wainwright reiterated a "buy" rating and issued a $30.00 target price on shares of Olema Pharmaceuticals in a report on Wednesday, November 13th. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has an average rating of "Buy" and a consensus price target of $27.00.
Read Our Latest Report on Olema Pharmaceuticals
Olema Pharmaceuticals Trading Up 10.4 %
The company has a fifty day simple moving average of $11.69 and a 200-day simple moving average of $11.90. The stock has a market cap of $497.94 million, a price-to-earnings ratio of -3.95 and a beta of 2.02.
Institutional Investors Weigh In On Olema Pharmaceuticals
Several hedge funds have recently made changes to their positions in the company. Conway Capital Management Inc. purchased a new stake in Olema Pharmaceuticals in the 3rd quarter worth about $119,000. China Universal Asset Management Co. Ltd. increased its stake in Olema Pharmaceuticals by 67.6% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 11,014 shares of the company's stock valued at $132,000 after buying an additional 4,442 shares during the period. Portland Investment Counsel Inc. purchased a new stake in shares of Olema Pharmaceuticals during the 3rd quarter worth about $143,000. SG Americas Securities LLC acquired a new position in Olema Pharmaceuticals during the 3rd quarter worth $156,000. Finally, Cubist Systematic Strategies LLC acquired a new position in Olema Pharmaceuticals during the 2nd quarter worth $145,000. Hedge funds and other institutional investors own 91.78% of the company's stock.
Olema Pharmaceuticals Company Profile
(
Get Free Report)
Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Olema Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Olema Pharmaceuticals wasn't on the list.
While Olema Pharmaceuticals currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for December 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.